Dutch pharma company Norgine opens new offices in Germany
Dutch pharma company Norgine has opened new offices in its largest product sales market – Germany at Wettenberg as part of its continued investment to support its growth strategy.
Norgine, which was established more than 110 years, acquires, develops, manufactures and commercializes products that address patients’ needs across specialist therapy areas. The areas of focus for the Dutch specialist pharma company, which boasts of a portfolio of well-known brands, are gastroenterology, hepatology, cancer and supportive care.
In Germany, Norgine has been present from 1928. It has a workforce of more than 100 in Germany, engaged in commercial, development and other support functions.
The major products of the Dutch pharma company in Germany are Plenvu, Xifaxan, Movicol, Dantrium, Moviprep and Lymphoseek.
Commenting on the opening of the new Norgine offices in Germany, Peter Stein – CEO of Norgine said: “We are confident that our new offices in Germany will help us to maintain the supply of our transformative products and high quality service to healthcare organisations and patients. We believe that this investment will continue to support our strong “One Norgine” team who share, with our partners a vision for improving patients’ lives.”
Norgine CEO Peter Stein officially opened the company’s new offices in Germany in an event that was attended by Prof. Dr. Helge Braun – the German Federal Minister for Special Affairs and Head of the Chancellery and Wettenberg Mayor Thomas Brunner.
Norgine, which recorded €345 million in net sales in 2017, has a direct commercial footprint in all important European markets.
The Dutch pharma company employs more than 1,000 people who work in its commercial, development and manufacturing operations and handle everything related to product development, production, marketing, sale and distribution.
For more pharma industry news and updates on Dutch pharma company Norgine, keep following PharmaNewsDaily.com.